10-Q: Oaktree Acquisition Corp. III Life Sciences Q1 2026 Update

Oaktree Acquisition Corp. III Life Sciences reports net income of $1.39 million for Q1 2026, driven by trust account interest, while continuing its search for a business combination.

Summary

• Oaktree Acquisition Corp. III Life Sciences (the Company) has filed its quarterly report for the period ending March 31, 2026.
• The Company reported a net income of $1,394,121 for the three months ended March 31, 2026, compared to $1,658,791 for the same period in 2025.
• This income was primarily derived from interest earned on its trust account, which held $203,414,191 as of March 31, 2026.
• General and administrative expenses for the quarter were $456,538, an increase from $444,802 in the prior year's quarter.
• The Company continues its search for a business combination and has not yet identified a specific target.
• As of March 31, 2026, the Company had $1,276,930 in cash and cash equivalents outside of the trust account.
• The Company faces substantial doubt about its ability to continue as a going concern due to potential liquidity shortfalls and the possibility of mandatory liquidation if a business combination is not consummated by October 25, 2026.
• The Company has until October 25, 2026, to complete a business combination, with potential options to extend this period subject to shareholder approval.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, reflecting the inherent uncertainty of a SPAC's pre-business combination stage. While the company has managed its expenses and generated interest income, the lack of operational progress and the looming deadline for a business combination introduce significant going concern risks.

Positives

• Generated net income of $1,394,121 for the quarter, primarily from interest income on the trust account.
• Maintained a significant balance in the trust account ($203,414,191 as of March 31, 2026) to support a future business combination.
• The company's disclosure controls and procedures were deemed effective as of March 31, 2026.

Negatives

• The company has no operating history and has not generated any operating revenues.
• The company has incurred general and administrative expenses of $456,538 for the quarter, impacting net income.
• There is substantial doubt about the Company's ability to continue as a going concern due to potential liquidity shortfalls and the risk of mandatory liquidation.
• The Company has not yet identified a target for its business combination, and there is no assurance it will be successful.
• The Company may need to raise additional capital, and there is no guarantee of success.

Risks

• The Company must complete a business combination within 24 months of its IPO (October 25, 2026), or it may face liquidation.
• If a business combination is not consummated, the Company may be forced to liquidate, and warrant holders may not receive any funds.
• The Sponsor may not be able to satisfy its indemnity obligations to the Trust Account, potentially impacting the funds available for redemption.
• Geopolitical events, such as military actions and sanctions, could materially and adversely affect the Company's ability to consummate a business combination or the operations of a target business.
• The Company's ability to raise additional capital may be impacted by market volatility and reduced liquidity.
• Shareholder redemptions in connection with a business combination or extensions of the combination period could materially adversely affect the amount held in the Trust Account.

Future Outlook

The Company's primary objective is to complete a business combination. It expects to continue incurring significant costs in pursuit of this goal. The Company has until October 25, 2026, to consummate a business combination, with potential options to extend this period subject to shareholder approval. Failure to complete a business combination by the deadline may result in the liquidation of the trust account and dissolution of the Company.

Management Comments

• The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans.
• The Company may need to raise additional capital through loans or additional investments from the Sponsor, shareholders, officers, directors, or third parties.
• The Company's officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company's working capital needs.
• There is no assurance that the Company's plans to raise additional capital will be successful.
• If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential Business Combination, and reducing overhead expenses.

Industry Context

StockSavvy.ai notes that Oaktree Acquisition Corp. III Life Sciences operates as a Special Purpose Acquisition Company (SPAC) focused on the life sciences sector. The current filing reflects the typical financial status of a SPAC in its pre-business combination phase, characterized by significant cash reserves held in trust, minimal operating expenses, and income derived from interest on these reserves, rather than operational revenue. The ongoing search for a target and the looming deadline for a business combination are critical factors for SPACs in this stage.

Comparison to Industry Standards

• As a SPAC, Oaktree Acquisition Corp. III Life Sciences' financial performance is not directly comparable to operating companies in the life sciences sector. Its primary financial metrics are related to its trust account balance and operational expenses.
• The net income of $1.39 million for the quarter, derived from interest income, is consistent with other SPACs that have raised substantial capital and are holding it in interest-bearing accounts while searching for a target.
• The general and administrative expenses of $456,538 are within the expected range for a SPAC of this size and stage, covering operational costs associated with maintaining its public status and search efforts.

Legal Proceedings

• None disclosed in the filing.

Related Party Transactions

• The Sponsor, Oaktree Acquisition Holdings III LS, LLC, is involved in several related party transactions, including the purchase of Private Placement Units and the provision of loans and administrative services.
• The Company pays the Sponsor $25,000 per month for office space, secretarial, and administrative services.
• As of March 31, 2026, $860,857 was due to the Sponsor for administrative services.
• A promissory note from a related party (Oaktree Acquisition Holdings III LS, L.P., assigned to the Sponsor) had $11,824 outstanding as of March 31, 2026.

Stakeholder Impact

• Shareholders: The primary concern for shareholders is the successful completion of a business combination within the specified timeframe. Failure to do so could result in liquidation and the loss of investment.
• Sponsor: The Sponsor has significant investment through private placement units and founder shares, and its success is tied to the completion of a business combination.
• Creditors: The Company has minimal liabilities outside of accrued expenses and deferred fees, suggesting limited immediate impact on creditors.

Next Steps

• Continue the search for a suitable business combination target.
• Evaluate potential business combination opportunities.
• Potentially seek shareholder approval to extend the combination period if necessary.
• If a business combination is not consummated by October 25, 2026, the Company may be subject to mandatory liquidation.

Key Dates

Recommendation

The filing represents a standard quarterly update for a SPAC. While the company is actively searching for a business combination, there are no new developments to suggest a significant shift in its prospects. The primary risks remain the deadline for a business combination and the potential for liquidation. Therefore, a 'hold' recommendation is appropriate, pending further information on a potential target or significant progress towards a business combination.

Keywords

SPAC, Oaktree Acquisition Corp. III Life Sciences, 10-Q, Quarterly Report, Business Combination, Trust Account, Life Sciences, Special Purpose Acquisition Company, Financial Statements, Emerging Growth Company